← All science articles

· 2 min read

Defibrotide Blocks Platelet Activation by Neutralizing an Immune Cell Enzyme

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Evangelista and colleagues, writing in Thrombosis and Haemostasis in 1992, studied defibrotide, a polydeoxyribonucleotide (a chain of DNA building blocks) already known for its antithrombotic, or clot-preventing, effects in animals. Until this paper, those effects had mostly been seen in live animal experiments, with little shown in laboratory (in vitro) systems.

Working with human cells in culture, the researchers found that defibrotide stopped polymorphonuclear leukocytes — a type of white blood cell — from triggering platelet activation, an early step in clot formation. The effect did not come from defibrotide acting directly on the leukocytes or the platelets themselves. Instead, the drug blocked cathepsin G, an enzyme released by these white blood cells that normally drives this cell-to-cell signaling.

Because cathepsin G also affects the cells lining blood vessels, the authors suggest that blocking this enzyme may be one reason defibrotide works against blood clots in the body. The study is laboratory-based and does not show whether this specific mechanism explains the drug's effects in patients, and it does not report any findings related to skin or tissue repair.

Our reflection

This 1992 paper is a reminder that polydeoxyribonucleotides have a long, rigorously studied pharmacological history well before their use in skin and tissue repair. Understanding how these molecules interact with specific enzymes and cells adds depth to the broader scientific foundation PDRN research rests on today. At Havdis, we see such mechanistic work as part of the deep roots supporting current interest in this ingredient class.

Source

Evangelista V, Piccardoni P, de Gaetano G, Cerletti C (1992). Thrombosis and haemostasis.

Read the paper on PubMed

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.